Ozempic Weight Loss: What Happens When You Stop Taking It
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to basket failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from Wish List failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
Ozempic Weight Loss: What Happens When You Stop Taking It
-
Narrated by:
-
By:
About this listen
A groundbreaking Cleveland Clinic study of nearly eight thousand patients reveals what happens when people stop GLP-1 drugs like Ozempic or tirzepatide. Those treated for obesity lost eight point four percent of body weight before stopping and regained just zero point five percent one year later. Many restarted the medication, switched to alternatives, or adopted lifestyle changes like dietitian visits, stabilizing their weight better than in clinical trials.
This contrasts with a UK meta-analysis in eClinicalMedicine, which found patients regain sixty percent of lost weight within one year after stopping, potentially plateauing at seventy-five percent. Experts stress pairing drugs with diet and exercise to sustain results, as regained weight may be mostly fat.
Exciting news on dosing: A small study in Obesity followed thirty patients on semaglutide or tirzepatide who spaced injections to every two weeks or more. After significant initial loss, they maintained weight, with BMI stable and even slight further drops in most. Healthline reports similar real-world success, noting it could cut costs and side effects while broadening access, though larger trials are needed.
Switching meds is common too. Powers Health reports only a quarter stick with one GLP-1 drug after a year, but switchers like from Ozempic to Zepbound are more likely to continue treatment.
Ozempic mimics gut hormones to curb appetite and aid digestion, leading to fifteen to twenty percent weight loss when combined with healthy habits, per Womens Health Mag. Its approved for type two diabetes but used off-label for obesity. Side effects include nausea, vomiting, and rare pancreatitis risks, so consult your doctor.
Emerging data from Memorial Sloan Kettering suggests potential cancer benefits from obesity-related weight loss.
Listeners, these updates show Ozempic as a powerful tool, but long-term success hinges on lifestyle. Talk to your healthcare provider.
Thank you for tuning in. Subscribe for more episodes. This has been a Quiet Please production. For more, check out Quiet Please dot ai.
Some great Deals https://amzn.to/49SJ3Qs
For more check out http://www.quietplease.ai
This content was created in partnership and with the help of Artificial Intelligence AI
No reviews yet
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.